Eric Allémann

Prof. Eric Allémann

Université de Genève
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Drug Discovery Today
Verified
Journal Article
Closed access
PMPierre Maudens
Pierre Maudens
Olivier JordanOlivier Jordan
Olivier Jordan
EAEric Allémann
Eric Allémann

1 February 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
JPJulie Pradal
Julie Pradal
PMPierre Maudens
Pierre Maudens
CGCem Gabay
Cem Gabay
CSChristian Alexander Seemayer
Christian Alexander Seemayer
Olivier JordanOlivier Jordan
Olivier Jordan
EAEric Allémann
Eric Allémann

1 May 2015 in Ultrasound in Medicine & Biology
Verified
Journal Article
Closed access
BPB. Petit
B. Petit
YBY. Bohren
Y. Bohren
EGE. Gaud
E. Gaud
PBP. Bussat
P. Bussat
MAM. Arditi
M. Arditi
EAEric Allémann
Eric Allémann

8 December 2017 in Nanoscale
Verified
Journal Article
Open access
PDF file
PMPierre Maudens
Pierre Maudens
SMSophie Meyer
Sophie Meyer
CSChristian Alexander Seemayer
Christian Alexander Seemayer
Olivier JordanOlivier Jordan
Olivier Jordan
EAEric Allémann
Eric Allémann
Under pathological conditions, joints and skin are often affected by an imbalance in the breakdown and production of hyaluronic acid (HA). The unique biochemical and biomechanical properties provided by HA must be restored for the long-term lubrication and cushioning effects. To overcome the inconvenience of repeated injections and the rapid degradation of exogenous HA treatments, HA is conjugated to a thermosensitive polymer, enabling the spontaneous formation of nanoparticles (HA Nano) at body temperature. Three HA Nano preparations are tested for their injectability, sensitivity to enzymatic degradation and cytocompatibility. One of them is delivered via subcutaneous and intra-articular injections to healthy mice and tested in a murine osteoarthritis (OA) model. It is found to be biocompatible, to offer a prolonged residence time at the injection site, have the ability to protect cartilage, to reduce pro-inflammatory cytokines and to preserve epiphysis thickness. In this study, HA Nano spontaneously forms nanoparticles at body temperature in vivo and is a promising candidate for the next generation of the sustainable/long-lasting treatment of OA and potentially also dermatological conditions.

7 March 2024 in Drug Delivery and Translational Research
Verified
Journal Article
Open access
PDF file
BRBenjamin Rossier
Benjamin Rossier
OJOlivier Jordan
Olivier Jordan
EAEric Allémann
Eric Allémann
CRCarlos Rodríguez-Nogales
Carlos Rodríguez-Nogales
Nanocrystals and nanosuspensions have become realistic approaches to overcome the formulation challenges of poorly water-soluble drugs. They also represent a less-known but versatile platform for multiple therapeutic applications. They can be integrated into a broad spectrum of drug delivery systems including tablets, hydrogels, microneedles, microparticles, or even functionalized liposomes. The recent progresses, challenges, and opportunities in this field are gathered originally together with an informative case study concerning an itraconazole nanosuspension-in-hydrogel formulation. The translational aspects, historical and current clinical perspectives are also critically reviewed here to shed light on the incoming generation of nanocrystal formulations.

25 July 2016 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
MPMarie Plissonneau
Marie Plissonneau
JPJonathan Pansieri
Jonathan Pansieri
LHLaurence Heinrich-Balard
Laurence Heinrich-Balard
JMJean-François Morfin
Jean-François Morfin
NSNathalie Stransky-Heilkron
Nathalie Stransky-Heilkron
CMChristel Marquette
Christel Marquette
Amyloidoses are characterized by the extracellular deposition of insoluble fibrillar proteinaceous aggregates highly organized into cross-β structure and referred to as amyloid fibrils. Nowadays, the diagnosis of these diseases remains tedious and involves multiple examinations while an early and accurate protein typing is crucial for the patients’ treatment. Routinely used neuroimaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) using Pittsburgh compound B, [11C]PIB, provide structural information and allow to assess the amyloid burden, respectively, but cannot discriminate between different amyloid deposits. Therefore, the availability of efficient multimodal imaging nanoparticles targeting specific amyloid fibrils would provide a minimally-invasive imaging tool useful for amyloidoses typing and early diagnosis. In the present study, we have functionalized gadolinium-based MRI nanoparticles (AGuIX) with peptides highly specific for Aβ amyloid fibrils, LPFFD and KLVFF. The capacity of such nanoparticles grafted with peptide to discriminate among different amyloid proteins, was tested with Aβ(1–42) fibrils and with mutated-(V30M) transthyretin (TTR) fibrils. The results of surface plasmon resonance studies showed that both functionalized nanoparticles interact with Aβ(1–42) fibrils with equilibrium dissociation constant (Kd) values of 403 and 350 µM respectively, whilst they did not interact with V30M-TTR fibrils. Similar experiments, performed with PIB, displayed an interaction both with Aβ(1–42) fibrils and V30M-TTR fibrils, with Kd values of 6 and 10 µM respectively, confirming this agent as a general amyloid fibril marker. Thereafter, the ability of functionalized nanoparticle to target and bind selectively Aβ aggregates was further investigated by immunohistochemistry on AD like-neuropathology brain tissue. Pictures clearly indicated that KLVFF-grafted or LPFFD-grafted to AGuIX nanoparticle recognized and bound the Aβ amyloid plaque localized in the mouse hippocampus. These results constitute a first step for considering these functionalized nanoparticles as a valuable multimodal imaging tool to selectively discriminate and diagnose amyloidoses.